Repisodic is proud to join the third cohort of the Science Center’s Digital Health Accelerator (DHA) in Philadelphia. Along with six other companies, repisodic will receive grant funding in the 12-month program to transition from product research and development to sales.
The DHA selects promising companies from around the world and provides them with funding, collaborative workspace, professional mentorship, and introductions to key healthcare stakeholders and investors in the Greater Philadelphia region. Companies are selected by a group of serial entrepreneurs and experts representing hospitals, the pharmaceutical industry, healthcare insurers/payers and investors. So far, 13 companies in the first two cohorts have created 160 jobs and generate more than $21 million in revenue.
The acceptance into the DHA is an important milestone and means a lot to the founding team at repisodic. The company grew out of late night brainstorms on the challenges the U.S. healthcare system faces as it deals with unsustainable increasing costs and the difficult transition to value based healthcare. Those exciting conversations drove repisodic’s co-founders to focus on the dysfunction and inefficiencies that patients experience when they are seeking follow-up post-acute care after an injury, illness or hospitalization.
While Repisodic’s database of post-acute care providers and patient facing online platform is already one of the most comprehensive free patient resources for follow-up care available anywhere, the investment and support from DHA will allow us to fully commercialize our solution and bring it into a clinical setting.
There is still a tremendous amount of hard work ahead, but all of us here at repisodic are encouraged by validation of our mission to improve patient care at such an early stage. We look forward to our work with DHA and future partners to bring our vision of getting patients to the best possible follow-up care every time a reality.
